Initial experience with CMC‐544 (inotuzumab ozogamicin) in pediatric patients with relapsed B‐cell acute lymphoblastic leukemia

Publisher： John Wiley & Sons Inc

E-ISSN： 1545-5017|61|2|369-372

ISSN： 1545-5009

Source： PEDIATRIC BLOOD & CANCER (ELECTRONIC), Vol.61, Iss.2, 2014-02, pp. : 369-372

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Prognostic factors for outcome in patients with refractory and relapsed acute lymphocytic leukemia treated with inotuzumab ozogamicin, a CD22 monoclonal antibody

By  

AMERICAN JOURNAL OF HEMATOLOGY, Vol. 90, Iss. 3, 2015-03 ,pp. : 193-196

John Wiley & Sons Inc

Access to resources Recommend Favorite

Cooperative genetic changes in pediatric B‐cell precursor acute lymphoblastic leukemia with deletions or mutations of IKZF1

By  

GENES, CHROMOSOMES AND CANCER, Vol. 54, Iss. 5, 2015-05 ,pp. : 315-325

John Wiley & Sons Inc

Access to resources Recommend Favorite

Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia in Adult Patients

By  

Acta Haematologica, Vol. 133, Iss. 1, 2014-08 ,pp. : 89-90

Karger

Access to resources Recommend Favorite

Gemtuzumab Ozogamicin (Mylotarg®) in Children with Refractory or Relapsed Acute Myeloid Leukemia

By  

Oncology Research and Treatment, Vol. 27, Iss. 3, 2004-07 ,pp. : 269-272

Karger

Access to resources Recommend Favorite

Acute Hepatitis A Induction of Precursor B-Cell Acute Lymphoblastic Leukemia:A Causal Relationship

By  

Case Reports in Oncology, Vol. 3, Iss. 3, 2010-12 ,pp. : 505-509

Karger

Access to resources Recommend Favorite